

**FORMATO EUROPEO
PER IL CURRICULUM
VITAE**



INFORMAZIONI PERSONALI

Nome MADDALENA BARBA
Indirizzo
Telefono
Fax
E-mail maddalena.barba@gmail.com
Nazionalità italiana
Data di nascita

ISTRUZIONE E FORMAZIONE

- Date (da – a) Novembre 2007-Settembre 2010
- Nome e tipo di istituto di istruzione o formazione Università La Sapienza, Roma
 - Principali materie / abilità professionali oggetto dello studio Oncologia Digestiva
 - Qualifica conseguita Dottorato di Ricerca
 - Livello nella classificazione nazionale (se pertinente)
- Date (da – a) Novembre 1997-Ottobre 2001
- Nome e tipo di istituto di istruzione o formazione Università Federico II, Napoli
 - Principali materie / abilità professionali oggetto dello studio Oncologia Medica
 - Qualifica conseguita Specializzazione
 - Livello nella classificazione nazionale (se pertinente)
- Date (da – a) Novembre 1990-Settembre 1996
- Nome e tipo di istituto di istruzione o formazione Università Federico II, Napoli
 - Principali materie / abilità professionali oggetto dello studio Medicina e Chirurgia
 - Qualifica conseguita Laurea cum Laude
 - Livello nella classificazione nazionale (se pertinente)

BORSE DI STUDIO

- Date (da – a) Luglio 2002-2005
- Nome e tipo di istituto di istruzione o formazione American Italian Cancer Foundation
 - Principali materie / abilità professionali oggetto dello studio Epidemiologia del Cancro
 - Qualifica conseguita Epidemiologo
 - Livello nella classificazione

nazionale (se pertinente)

ESPERIENZA LAVORATIVA- PROFESSIONALE

- Date Gennaio 2012-present
- Nome e indirizzo del datore di lavoro Oncologia Medica 2, Istituto Nazionale Tumori Regina Elena, Roma, Italia
- Tipo di azienda o settore IRCCS
- Tipo di impiego Collaborazione Coordinata e Continuativa in ambito di Ricerca Scientifica applicata all'area Medica
- Principali mansioni e responsabilità Ricercatore Senior nel Setting Clinico e traslazionale.

- Date July 2013-present
- Nome e indirizzo del datore di lavoro Ufficio III, Ricerca Scientifica IRCCSS
- Tipo di azienda o settore Ministero della Salute
- Tipo di impiego Collaborazione Coordinata e Continuativa in ambito di Ricerca Scientifica applicata all'area Medica
- Principali mansioni e responsabilità Consulente Scientifico

- Date June 2005 – April 2015
- Nome e indirizzo del datore di lavoro Epidemiologia Oncologica, Istituto Nazionale Tumori Regina Elena, Rome, Italy.
- Tipo di azienda o settore IRCCS
- Tipo di impiego Collaborazione Coordinata e Continuativa in ambito di Ricerca Scientifica applicata all'area Medica
- Principali mansioni e responsabilità Ricercatore Junior

- Date Luglio 2002-June 2005: Disegno e conduzione di studi osservazionali in materia oncologica
- Nome e indirizzo del datore di lavoro State University of New York
- Tipo di impiego Borsa di Studio erogata dall'American Italian Cancer Foundation per la conduzione di un progetto con focus sulla patologia neoplastica mammaria
- Principali mansioni e responsabilità Ricercatore Junior

- Nome e indirizzo del datore di lavoro Istituto Nazionale Tumori Regina Elena, Roma

Attività integrative e satelliti (presenti e passate)

Professore Aggiunto alla Temple University, Centre for Cancer Research and Molecular Medicine, Temple University, PA, USA (2010-present).

Consulente scientifico per programmi di screening relativi al cancro mammario, della cervice uterina e coloretto presso il CRPO (Centro Regionale Prevenzione Oncologica), Federico II, Napoli (2006-09).

Grant Reviewer per la Direzione Scientifica della Fondazione G. Pascale su invite del Direttore G. Ciliberto (2012).

Reviewer per la UICC (Unione Internazionale Contro il Cancro) (2014, 2012 and 2010)

Grant reviewer per la Canadian Breast Cancer Foundation (2005-6)

Grant reviewer per l'Alberta Cancer Board (2004)

Insegnamento accademico:

Seminar for SPM 621, Advanced Topics in Cancer Epidemiology, "Biology of cancer", September 23rd, 2003. Department of Social and Preventive Medicine, State University of New York, Buffalo, New York.

Seminar for the Department of Endocrinology and Oncology of Federico II Medical school of Naples, "DNA-adducts and breast cancer risk", January 7th, 2004.

Seminar within the SPM seminars series, "Total and beverage specific lifetime alcohol intake and risk of prostate cancer", March 5th, 2004. Department of Social and Preventive Medicine, State University of New York, Buffalo, New York.

Seminar for SPM 614, Molecular Epidemiology, "Screening in Cancer Epidemiology", October 1st, 2004. Department of Social and Preventive Medicine, State University of New York, Buffalo, New York.

Teaching Course: Fundamentals in Clinical Epidemiology. Unit of Epidemiology, University of Padua, May the 14th, 2008.

Teaching Course: Fundamentals in Clinical Epidemiology and Biostatistics. La Sapienza University of Rome (Residency Program in Medical Oncology), November (24)-December (1 and 9) 2008.

Workshop: Prevention Strategies in Breast Cancer. G. Pascale Foundation National Cancer Institute of Naples, March (15) 2013.

Systematic Reviews of Intervention Trials: from the research question to results' interpretation. Regina Elena National Cancer Institute, Rome, April (11) 2013.

Invited Reviewer per le seguenti riviste scientifiche

Annals of Internal Medicine (2016)

Lancet Oncology (2016)

International Journal of Cancer (2016)

BJC (2014)

PLOS ONE (2013-14)

Nutrition Journal (2013)

International Journal of Cancer (2012-2013)

Systems Biology in Reproductive Medicine (2011)

Biomarkers (2010, 2013)

The International Journal of Biological Markers (2010)

Cancer Epidemiology, Biomarkers & Prevention (2008)

JAMA (2007)

British Medical Journal (2007)

Journal Experimental & Clinical Cancer Research (2005-2006, 2012-13)

European Journal of Clinical Nutrition (2005)

Pubblicazioni su riviste scientifiche

1. Long-Term Safety and Real-World Effectiveness of Trastuzumab in Breast Cancer. Mazzotta M, Krasniqi E, Barchiesi G, Pizzuti L, Tomao F, **Barba M**, Vici P. J Clin Med. 2019 Feb 18;8(2).

pii: E254. doi: 10.3390/jcm8020254. Review.

2. Combination of peripheral neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio is predictive of pathological complete response after neoadjuvant chemotherapy in breast cancer patients. Graziano V, Grassadonia A, Iezzi L, Vici P, Pizzuti L, **Barba M**, Quinzii A, Campese A, Di Marino P, Peri M, Veschi S, Alberti S, Gamucci T, Di Gioacchino M, De Tursi M, Natoli C, Tinari N. *Breast*. 2019 Apr;44:33-38. doi: 10.1016/j.breast.2018.12.014. Epub 2019 Jan 2.
3. Effect of Gender on the Outcome of Patients Receiving Immune Checkpoint Inhibitors for Advanced Cancer: A Systematic Review and Meta-Analysis of Phase III Randomized Clinical Trials. Grassadonia A, Sperduti I, Vici P, Iezzi L, Brocco D, Gamucci T, Pizzuti L, Maugeri-Saccà M, Marchetti P, Cognetti G, De Tursi M, Natoli C, **Barba M**, Tinari N. *J Clin Med*. 2018 Dec 12;7(12). pii: E542. doi: 10.3390/jcm7120542.
4. Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer: A real-world experience. Pizzuti L, Giordano A, Michelotti A, Mazzotta M, Natoli C, Gamucci T, De Angelis C, Landucci E, Diodati L, Iezzi L, Mentuccia L, Fabbri A, **Barba M**, Sanguineti G, Marchetti P, Tomao S, Mariani L, Paris I, Lorusso V, Vallarelli S, Cassano A, Airolidi F, Orlandi A, Moschetti L, Sergi D, Sarobba MG, Tonini G, Santini D, Sini V, Veltri E, Vaccaro A, Ferrari L, De Tursi M, Tinari N, Grassadonia A, Greco F, Botticelli A, La Verde N, Zamagni C, Rubino D, Cortesi E, Magri V, Pomati G, Scagnoli S, Capomolla E, Kayal R, Scinto AF, Corsi D, Cazzaniga M, Laudadio L, Forciniti S, Mancini M, Carbognin L, Seminara P, Barni S, Samaritani R, Roselli M, Portarena I, Russo A, Ficorella C, Cannita K, Carpano S, Pistelli M, Berardi R, De Maria R, Sperduti I, Ciliberto G, Vici P. *J Cell Physiol*. 2019 Jun;234(6):7708-7717. doi: 10.1002/jcp.27832. Epub 2018 Dec 10.
5. A multicenter REtrospective observational study of first-line treatment with PERTuzumab, trastuzumab and taxanes for advanced HER2 positive breast cancer patients. RePer Study. Gamucci T, Pizzuti L, Natoli C, Mentuccia L, Sperduti I, **Barba M**, Sergi D, Iezzi L, Maugeri-Saccà M, Vaccaro A, Magnolfi E, Gelibter A, Barchiesi G, Magri V, D'Onofrio L, Cassano A, Rossi E, Botticelli A, Moschetti L, Omarini C, Fabbri MA, Scinto AF, Corsi D, Carbognin L, Mazzotta M, Bria E, Foglietta J, Samaritani R, Garufi C, Mariani L, Barni S, Mirabelli R, Sarmiento R, Graziano V, Santini D, Marchetti P, Tonini G, Di Lauro L, Sanguineti G, Paoletti G, Tomao S, De Maria R, Veltri E, Paris I, Giotta F, Latorre A, Giordano A, Ciliberto G, Vici P.
6. The clinical significance of PD-L1 in advanced gastric cancer is dependent on *ARID1A* mutations and ATM expression. Buglioni S, Melucci E, Sperati F, Pallocca M, Terrenato I, De Nicola F, Goeman F, Casini B, Amoreo CA, Gallo E, Diodoro MG, Pescarmona E, Vici P, Sergi D, Pizzuti L, Di Lauro L, Mazzotta M, **Barba M**, Fanciulli M, Vitale I, De Maria R, Ciliberto G, Maugeri-Saccà M. *Oncoimmunology*. 2018 Apr 24;7(8):e1457602. doi: 10.1080/2162402X.2018.1457602. eCollection 2018.
7. Coexisting YAP expression and TP53 missense mutations delineates a molecular scenario unexpectedly associated with better survival outcomes in advanced gastric cancer. Pallocca M, Goeman F, De Nicola F, Melucci E, Sperati F, Terrenato I, Pizzuti L, Casini B, Gallo E, Amoreo CA, Vici P, Di Lauro L, Buglioni S, Diodoro MG, Pescarmona E, Mazzotta M, **Barba M**, Fanciulli M, De Maria R, Ciliberto G, Maugeri-Saccà M. *J Transl Med*. 2018 Sep 4;16(1):247. doi: 10.1186/s12967-018-1607-3.
8. Deep sequencing and pathway-focused analysis revealed multigene oncodriver signatures predicting survival outcomes in advanced colorectal cancer. De Nicola F, Goeman F, Pallocca M, Sperati F, Pizzuti L, Melucci E, Casini B, Amoreo CA, Gallo E, Diodoro MG, Buglioni S, Mazzotta M, Vici P, Sergi D, Di Lauro L, **Barba M**, Pescarmona E, Ciliberto G, De Maria R, Fanciulli M, Maugeri-Saccà M. *Oncogenesis*. 2018 Jul 22;7(7):55. doi: 10.1038/s41389-018-0066-2.
9. Anticoagulation for perioperative thromboprophylaxis in people with cancer. Matar CF, Kahale LA, Hakoum MB, Tsolakian IG, Etzeandia-Ikobaltzeta I, Yosucio VE, Terrenato I, Sperati F, **Barba M**, Schünemann H, Akl EA. *Cochrane Database Syst Rev*. 2018 Jul 11;7:CD009447. doi:

10.1002/14651858.CD009447.pub3. Review.

10. Anticoagulation for the long-term treatment of venous thromboembolism in people with cancer. Kahale LA, Hakoum MB, Tsolakian IG, Matar CF, Terrenato I, Sperati F, **Barba M**, Yosunico VE, Schünemann H, Akl EA. *Cochrane Database Syst Rev*. 2018 Jun 19;6:CD006650. doi: 10.1002/14651858.CD006650.pub5. Review.
11. Anticoagulation for people with cancer and central venous catheters. Kahale LA, Tsolakian IG, Hakoum MB, Matar CF, **Barba M**, Yosunico VE, Terrenato I, Sperati F, Schünemann H, Akl EA. *Cochrane Database Syst Rev*. 2018 Jun 1;6:CD006468. doi: 10.1002/14651858.CD006468.pub6. Review.
12. Observational study of coagulation activation in early breast cancer: development of a prognostic model based on data from the real world setting. Mandoj C, Pizzuti L, Sergi D, Sperduti I, Mazzotta M, Di Lauro L, Amodio A, Carpano S, Di Benedetto A, Botti C, Ferranti F, Antenucci A, D'Alessandro MG, Marchetti P, Tomao S, Sanguineti G, Giordano A, Maugeri-Saccà M, Ciliberto G, Conti L, Vici P, **Barba M**. *J Transl Med*. 2018 May 16;16(1):129. doi: 10.1186/s12967-018-1511-x.
13. Indirect Basal Metabolism Estimation in Tailoring Recombinant Human TSH Administration in Patients Affected by Differentiated Thyroid Cancer: A Hypothesis-Generating Study. Barnabei A, Strigari L, Persichetti A, Baldelli R, Rizza L, Annoscia C, Lauretta R, Cigliana G, **Barba M**, De Leo A, Appetecchia M, Torino F. *Front Endocrinol (Lausanne)*. 2018 Feb 15;9:37. doi: 10.3389/fendo.2018.00037. eCollection 2018.
14. Expression of the Hippo transducer TAZ in association with WNT pathway mutations impacts survival outcomes in advanced gastric cancer patients treated with first-line chemotherapy. Melucci E, Casini B, Ronchetti L, Pizzuti L, Sperati F, Pallocca M, De Nicola F, Goeman F, Gallo E, Amoreo CA, Sergi D, Terrenato I, Vici P, Di Lauro L, Diodoro MG, Pescarmona E, **Barba M**, Mazzotta M, Mottolese M, Fanciulli M, Ciliberto G, De Maria R, Buglioni S, Maugeri-Saccà M. *J Transl Med*. 2018 Feb 5;16(1):22. doi: 10.1186/s12967-018-1385-y.
15. Anticoagulation for the initial treatment of venous thromboembolism in people with cancer. Hakoum MB, Kahale LA, Tsolakian IG, Matar CF, Yosunico VE, Terrenato I, Sperati F, **Barba M**, Schünemann H, Akl EA. *Cochrane Database Syst Rev*. 2018 Jan 24;1:CD006649. doi: 10.1002/14651858.CD006649.pub7. Review.
16. Body mass index in HER2-negative metastatic breast cancer treated with first-line paclitaxel and bevacizumab. Pizzuti L, Sergi D, Sperduti I, Lauro LD, Mazzotta M, Botti C, Izzo F, Marchetti L, Tomao S, Marchetti P, Natoli C, Grassadonia A, Gamucci T, Mentuccia L, Magnolfi E, Vaccaro A, Cassano A, Rossi E, Botticelli A, Sini V, Sarobba MG, Fabbri MA, Moscetti L, Astone A, Michelotti A, De Angelis C, Bertolini I, Angelini F, Ciliberto G, Maugeri-Saccà M, Giordano A, **Barba M**, Vici P. *Cancer Biol Ther*. 2018 Apr 3;19(4):328-334. doi: 10.1080/15384047.2017.1416938. Epub 2018 Feb 16.
17. Oral anticoagulation in people with cancer who have no therapeutic or prophylactic indication for anticoagulation. Kahale LA, Hakoum MB, Tsolakian IG, Matar CF, **Barba M**, Yosunico VED, Terrenato I, Sperati F, Schünemann H, Akl EA. *Cochrane Database Syst Rev*. 2017 Dec 29;12:CD006466. doi: 10.1002/14651858.CD006466.pub6. Review.
18. Anthropometric, clinical and molecular determinants of treatment outcomes in postmenopausal, hormone receptor positive metastatic breast cancer patients treated with fulvestrant: Results from a real word setting. Pizzuti L, Natoli C, Gamucci T, Mauri M, Sergi D, Di Lauro L, Paoletti G, Ruggeri E, Iezzi L, Sperduti I, Mentuccia L, Fabbri A, Maugeri-Saccà M, Moscetti L, **Barba M**, Vici P. *Oncotarget*. 2017 Apr 9;8(40):69025-69037. doi: 10.18632/oncotarget.16982. eCollection 2017 Sep 15.
19. A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: a real-world experience. Vici P, Pizzuti L, Michelotti A, Sperduti I,

- Natoli C, Mentuccia L, Di Lauro L, Sergi D, Marchetti P, Santini D, Magnolfi E, Iezzi L, Moscetti L, Fabbri A, Cassano A, Grassadonia A, Omarini C, Piacentini F, Botticelli A, Bertolini I, Scinto AF, Zampa G, Mauri M, D'Onofrio L, Sini V, **Barba M**, Maugeri-Saccà M, Rossi E, Landucci E, Tomao S, Alberti AM, Giotta F, Ficorella C, Adamo V, Russo A, Lorusso V, Cannita K, Barni S, Laudadio L, Greco F, Garrone O, Della Giulia M, Marolla P, Sanguineti G, Di Cocco B, Ciliberto G, De Maria R, Gamucci T. *Oncotarget*. 2017 May 25;8(34):56921-56931. doi: 10.18632/oncotarget.18176. eCollection 2017 Aug 22.
20. Fulvestrant 500 milligrams as endocrine therapy for endocrine sensitive advanced breast cancer patients in the real world: the Ful500 prospective observational trial. Moscetti L, Fabbri MA, Natoli C, Vici P, Gamucci T, Sperduti I, Iezzi L, Iattoni E, Pizzuti L, Roma C, Vaccaro A, D'Auria G, Mauri M, Mentuccia L, Grassadonia A, **Barba M**, Ruggeri EM. *Oncotarget*. 2017 Apr 20;8(33):54528-54536. doi: 10.18632/oncotarget.17262. eCollection 2017 Aug 15.
 21. Parenteral anticoagulation in ambulatory patients with cancer. Akl EA, Kahale LA, Hakoum MB, Matar CF, Sperati F, **Barba M**, Yosucio VED, Terrenato I, Synnot A, Schünemann H. *Cochrane Database Syst Rev*. 2017 Sep 11;9:CD006652. doi: 10.1002/14651858.CD006652.pub5. Review.
 22. Fasting glucose and body mass index as predictors of activity in breast cancer patients treated with everolimus-exemestane: The EverExt study. Pizzuti L, Marchetti P, Natoli C, Gamucci T, Santini D, Scinto AF, Iezzi L, Mentuccia L, D'Onofrio L, Botticelli A, Moscetti L, Sperati F, Botti C, Ferranti F, Buglioni S, Sanguineti G, Di Filippo S, di Lauro L, Sergi D, Catenaro T, Tomao S, Giordano A, Maugeri-Saccà M, **Barba M**, Vici P. *Sci Rep*. 2017 Sep 6;7(1):10597. doi: 10.1038/s41598-017-10061-2.
 23. Analysis of the ATR-Chk1 and ATM-Chk2 pathways in male breast cancer revealed the prognostic significance of ATR expression. Di Benedetto A, Ercolani C, Mottolese M, Sperati F, Pizzuti L, Vici P, Terrenato I, Shaaban AM, Humphries MP, Di Lauro L, **Barba M**, Vitale I, Ciliberto G, Speirs V, De Maria R, Maugeri-Saccà M. *Sci Rep*. 2017 Aug 14;7(1):8078. doi: 10.1038/s41598-017-07366-7.
 24. Iodixanol versus iopromide in cancer patients: Evidence from a randomized clinical trial. Terrenato I, Sperati F, Musicco F, Pozzi AF, di Turi A, Caterino M, de Lutio di Castelguidone E, Setola SV, Bellomi M, Neumaier CE, Conti L, Cigliana G, Merola R, Antenucci A, Orlandi G, Giordano A, **Barba M**, Canitano S. *J Cell Physiol*. 2018 Mar;233(3):2572-2580. doi: 10.1002/jcp.26132. Epub 2017 Sep 12.
 25. Neoadjuvant chemotherapy in triple-negative breast cancer: A multicentric retrospective observational study in real-life setting. Gamucci T, Pizzuti L, Sperduti I, Mentuccia L, Vaccaro A, Moscetti L, Marchetti P, Carbognin L, Michelotti A, Iezzi L, Cassano A, Grassadonia A, Astone A, Botticelli A, Magnolfi E, Di Lauro L, Sergi D, Fuso P, Tinari N, **Barba M**, Maugeri-Saccà M, Landucci E, Conti F, Sanguineti G, De Tursi M, Iafrate G, Giordano A, Ciliberto G, Natoli C, Vici P. *J Cell Physiol*. 2018 Mar;233(3):2313-2323. doi: 10.1002/jcp.26103. Epub 2017 Sep 27.
 26. GLUT 1 receptor expression and circulating levels of fasting glucose in high grade serous ovarian cancer. Pizzuti L, Sergi D, Mandoj C, Antoniani B, Sperati F, Chirico A, Di Lauro L, Valle M, Garofalo A, Vizza E, Corrado G, Tomao F, Rinaldi M, Carpano S, Maugeri-Saccà M, Conti L, Digiesi G, Marchetti P, De Maria R, Giordano A, **Barba M**, Carosi MA, Vici P. *J Cell Physiol*. 2018 Feb;233(2):1396-1401. doi: 10.1002/jcp.26023. Epub 2017 Jul 14.
 27. ESAS and FACT-B in eribulin-treated metastatic breast cancer patients: a multicenter, prospective and observational study. Moscetti L, Mentuccia L, Vici P, Quadrini S, Sperduti I, Pizzuti L, Fabbri MA, Vaccaro A, Maugeri-Saccà M, **Barba M**, Sergi D, Zampa G, Gamucci T. *Future Oncol*. 2017 Jul;13(17):1517-1525. doi: 10.2217/fon-2017-0062. Epub 2017 Apr 21.

28. Gamucci T, Pizzuti L, Sperduti I, Mentuccia L, Vaccaro A, Moscetti L, Marchetti P, Carbognin L, Michelotti A, Iezzi L, Cassano A, Grassadonia A, Astone A, Botticelli A, Magnolfi E, Di Lauro L, Sergi D, Fuso P, Tinari N, **Barba M**, Maugeri-Saccà M, Landucci E, Conti F, Sanguineti G, De Tursi M, Iafrate G, Giordano A, Ciliberto G, Natoli C, Vici P. Neoadjuvant Chemotherapy In Triple-Negative Breast Cancer: A Multicentric Retrospective Observational Study In Real-Life Setting. *J Cell Physiol*. 2017 Jul 15. doi: 10.1002/jcp.26103.
29. Vici P, Pizzuti L, Michelotti A, Sperduti I, Natoli C, Mentuccia L, Di Lauro L, Sergi D, Marchetti P, Santini D, Magnolfi E, Iezzi L, Moscetti L, Fabbri A, Cassano A, Grassadonia A, Omarini C, Piacentini F, Botticelli A, Bertolini I, Scinto AF, Zampa G, Mauri M, D'Onofrio L, Sini V, **Barba M**, Maugeri-Saccà M, Rossi E, Landucci E, Tomao S, Alberti AM, Giotta F, Ficorella C, Adamo V, Russo A, Lorusso V, Cannita K, Barni S, Laudadio L, Greco F, Garrone O, Giulia MD, Marolla P, Sanguineti G, Di Cocco B, Ciliberto G, De Maria R, Gamucci T. A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: a real-world experience. *Oncotarget*. 2017 May 25. doi: 10.18632/oncotarget.18176.
30. Pizzuti L, Sergi D, Mandoj C, Antoniani B, Sperati F, Chirico A, Di Lauro L, Valle M, Garofalo A, Vizza E, Corrado G, Tomao F, Rinaldi M, Carpano S, Maugeri-Saccà M, Conti L, Digiesi G, Marchetti P, De Maria R, Giordano A, **Barba M***, Carosi MA, Vici P. GLUT 1 receptor expression and circulating levels of fasting glucose in high grade serous ovarian cancer. *J Cell Physiol*. 2017 May 20. doi: 10.1002/jcp.26023.
31. Moscetti L, Fabbri MA, Natoli C, Vici P, Gamucci T, Sperduti I, Iezzi L, Iattoni E, Pizzuti L, Roma C, Vaccaro A, D'Auria G, Mauri M, Mentuccia L, Grassadonia A, **Barba M**, Ruggeri EM. Fulvestrant 500 milligrams as endocrine therapy for endocrine sensitive advanced breast cancer patients in the real world: the Ful500 prospective observational trial. *Oncotarget*. 2017 Apr 20. doi: 10.18632/oncotarget.17262.
32. Pizzuti L, Natoli C, Gamucci T, Mauri M, Sergi D, Di Lauro L, Paoletti G, Ruggeri E, Iezzi L, Sperduti I, Mentuccia L, Fabbri A, Maugeri-Saccà M, Moscetti L, **Barba M***, Vici P. Anthropometric, clinical and molecular determinants of treatment outcomes in postmenopausal, hormone receptor positive metastatic breast cancer patients treated with fulvestrant. Results from a real word setting. *Oncotarget*. 2017 Apr 9. doi: 10.18632/oncotarget.16982.
33. Moscetti L, Mentuccia L, Vici P, Quadrini S, Sperduti I, Pizzuti L, Fabbri MA, Vaccaro A, Maugeri-Saccà M, **Barba M**, Sergi D, Zampa G, Gamucci T. ESAS and FACT-B in eribulin-treated metastatic breast cancer patients: a multicenter, prospective and observational study. *Future Oncol*. 2017 Apr 21. doi: 10.2217/fo-2017-0062. [Epub ahead of print]
34. Ercolani C, Di Benedetto A, Terrenato I, Pizzuti L, Di Lauro L, Sergi D, Sperati F, Buglioni S, Ramieri MT, Mentuccia L, Gamucci T, Perracchio L, Pescarmona E, Mottolese M, **Barba M**, Vici P, De Maria R, Maugeri-Saccà M. Expression of phosphorylated Hippo pathway kinases (MST1/2 and LATS1/2) in HER2-positive and triple-negative breast cancer patients treated with neoadjuvant therapy. *Cancer Biol Ther*. 2017 May 4;18(5):339-346. doi: 10.1080/15384047.2017.1312230. Epub 2017 Apr 7.

***Corresponding author**

35. Ronchetti L, Melucci E, De Nicola F, Goeman F, Casini B, Sperati F, Pallocca M, Terrenato I, Pizzuti L, Vici P, Sergi D, Di Lauro L, Amoreo CA, Gallo E, Diodoro MG, Pescarmona E, Vitale I, **Barba M**, Buglioni S, Mottolese M, Fanciulli M, De Maria R, Maugeri-Saccà M. DNA damage repair and survival outcomes in advanced gastric cancer patients treated with first-line chemotherapy. *Int J Cancer*. 2017 Feb 24. doi: 10.1002/ijc.30668.
36. **Barba M**, Vici P, Pizzuti L, Di Lauro L, Sergi D, Di Benedetto A, Ercolani C, Sperati F, Terrenato I, Botti C, Mentuccia L, Iezzi L, Gamucci T, Natoli C, Vitale I, Mottolese M, De Maria R, Maugeri-Saccà M. Body mass index modifies the relationship between γ -H2AX, a DNA damage biomarker, and pathological complete response in triple-negative breast cancer. *BMC Cancer*. 2017 Feb 6;17(1):101. doi: 10.1186/s12885-016-3045-z.
37. Di Benedetto A, Mottolese M, Sperati F, Ercolani C, Di Lauro L, Pizzuti L, Vici P, Terrenato I, Sperduti I, Shaaban AM, Sundara-Rajan S, **Barba M**, Speirs V, De Maria R, Maugeri-Saccà M. The Hippo transducers TAZ/YAP and their target CTGF in male breast cancer. *Oncotarget*. 2016 May 27. doi: 10.18632/oncotarget.9668. [
38. Pizzuti L, **Barba M**, Giannarelli D, Sergi D, Botti C, Marchetti P, Anzà M, Maugeri-Saccà M, Natoli C, Filippo SD, Catenaro T, Tomao F, Amodio A, Carpano S, Perracchio L, Mottolese M, Lauro LD, Sanguineti G, Benedetto AD,

Giordano A, Vici P. Neoadjuvant sequential docetaxel followed by high-dose epirubicin in combination with cyclophosphamide administered concurrently with trastuzumab: The DECT trial. *J Cell Physiol.* 2016 May 17. doi: 10.1002/jcp.25432.

39. Vici P, Ercolani C, Di Benedetto A, Pizzuti L, Di Lauro L, Sperati F, Terrenato I, Gamucci T, Natoli C, Di Filippo F, Botti C, **Barba M**, Mottolese M, De Maria R, Maugeri-Saccà M. Topographic expression of the Hippo transducers TAZ and YAP in triple-negative breast cancer treated with neoadjuvant chemotherapy. *J Exp Clin Cancer Res.* 2016 Apr 2;35(1):62. doi: 10.1186/s13046-016-0338-7.
40. Vici P, Pizzuti L, Di Lauro L, Conti L, Mandoj C, Antenucci A, Digiesi G, Sergi D, Amodio A, Marchetti P, Sperati F, Valle M, Garofalo A, Vizza E, Corrado G, Vincenzoni C, Tomao F, Kayal R, Marsella A, Carosi M, Antoniani B, Giordano A, Maugeri-Saccà M, **Barba M**. Metabolic Determinants and Anthropometric Indicators Impact Clinical-pathological Features in Epithelial Ovarian Cancer Patients. *J Cancer.* 2016 Feb 10;7(5):516-22. doi: 10.7150/jca.13578.
41. D'Aiuto M, Chirico A, De Riggi MA, Frasci G, De Laurentiis M, Di Bonito M, Vici P, Pizzuti L, Sergi D, Maugeri-Saccà M, **Barba M**, Giordano A. Body mass index and treatment outcomes following neoadjuvant therapy in women aged 45 y or younger: Evidence from a historic cohort. *Cancer Biol Ther.* 2016 May 3;17(5):470-6. doi: 10.1080/15384047.2016.1156265. Epub 2016 Mar 2.
42. Vici P, Buglioni S, Sergi D, Pizzuti L, Di Lauro L, Antoniani B, Sperati F, Terrenato I, Carosi M, Gamucci T, Dattilo R, Bartucci M, Vincenzoni C, Mariani L, Vizza E, Sanguineti G, Gadducci A, Vitale I, **Barba M**, De Maria R, Mottolese M, Maugeri-Saccà MDNA Damage and Repair Biomarkers in Cervical Cancer Patients Treated with Neoadjuvant Chemotherapy: An Exploratory Analysis. *PLoS One.* 2016 Mar 1;11(3):e0149872. doi: 10.1371/journal.pone.0149872. eCollection 2016.
43. Vici P, Pizzuti L, Sperduti I, Frassoldati A, Natoli C, Gamucci T, Tomao S, Michelotti A, Moscetti L, Gori S, Baldini E, Giotta F, Cassano A, Santini D, Giannarelli D, Di Lauro L, Corsi DC, Marchetti P, Sini V, Sergi D, **Barba M**, Maugeri-Saccà M, Russillo M, Mentuccia L, D'Onofrio L, Iezzi L, Scinto AF, Da Ros L, Bertolini I, Basile ML, Rossi V, De Maria R, Montemurro F. "Triple positive" early breast cancer: an observational multicenter retrospective analysis of outcome. *Oncotarget.* 2016 Feb 18. doi: 10.18632/oncotarget.7480.
44. Vici P, Di Benedetto A, Ercolani C, Pizzuti L, Di Lauro L, Sergi D, Sperati F, Terrenato I, Dattilo R, Botti C, Fabi A, Ramieri MT, Mentuccia L, Marinelli C, Iezzi L, Gamucci T, Natoli C, Vitale I, **Barba M**, Mottolese M, De Maria R, Maugeri-Saccà M. Predictive significance of DNA damage and repair biomarkers in triple-negative breast cancer patients treated with neoadjuvant chemotherapy: An exploratory analysis. *Oncotarget.* 2015 Oct 17.
45. **Barba M**, Pizzuti L, Sperduti I, Natoli C, Gamucci T, Sergi D, Di Lauro L, Moscetti L, Izzo F, Rinaldi M, Mentuccia L, Vaccaro A, Iezzi L, Grassadonia A, Michelotti A, Perracchio L, Pescarmona E, Di Filippo F, Giordano A, Maugeri-Saccà M, Vici P. Body Mass Index and Treatment Outcomes in Metastatic Breast Cancer Patients Treated with Eribulin. *J Cell Physiol.* 2015 Oct 9.
46. Di Lauro L, **Barba M**, Pizzuti L, Vici P, Sergi D, Di Benedetto A, Mottolese M, Speirs V, Santini D, De Maria R, Maugeri-Saccà M. Androgen receptor and antiandrogen therapy in male breast cancer. *Cancer Lett.* 2015 Nov 1;368(1):20-5. doi: 10.1016/j.canlet.2015.07.040. Epub 2015 Aug 11.
47. Maugeri-Saccà M, **Barba M**, Pizzuti L, Vici P, Di Lauro L, Dattilo R, Vitale I, Bartucci M, Mottolese M, De Maria R. The Hippo transducers TAZ and YAP in breast cancer: oncogenic activities and clinical implications. *Expert Rev Mol Med.* 2015 Jul 2;17:e14. doi: 10.1017/erm.2015.12.
48. Di Lauro L, Pizzuti L, **Barba M**, Sergi D, Sperduti I, Mottolese M, Amoreo CA, Belli F, Vici P, Speirs V, Santini D, De Maria R, Maugeri-Saccà M. Role of gonadotropin-releasing hormone analogues in metastatic male breast cancer: results from a pooled analysis. *J Hematol Oncol.* 2015 May 17;8:53. doi: 10.1186/s13045-015-0147-z.
49. L, Pizzuti L, **Barba M**, Sergi D, Sperduti I, Mottolese M, Del Medico P, Belli F, Vici P, De Maria R, Maugeri-Saccà M. Efficacy of chemotherapy in metastatic male breast cancer patients: a retrospective study. *Di Lauro J Exp Clin Cancer Res.* 2015 Mar 21;34:26. doi: 10.1186/s13046-015-0143-8.
50. Pizzuti L, Vici P, Di Lauro L, Sergi D, Della Giulia M, Marchetti P, Maugeri-Saccà M, Giordano A, **Barba M**. Metformin and breast cancer: basic knowledge in clinical context. *Cancer Treat Rev.* 2015 May;41(5):441-7. doi: 10.1016/j.ctrv.2015.03.002. Epub 2015 Mar 17. Review.
51. Vici P, Pizzuti L, Natoli C, Gamucci T, Di Lauro L, **Barba M**, Sergi D, Botti C, Michelotti A, Moscetti L, Mariani L, Izzo F, D'Onofrio L, Sperduti I, Conti F, Rossi V, Cassano A, Maugeri-Saccà M, Mottolese M, Marchetti P. Triple positive breast cancer: A distinct subtype? *Cancer Treat Rev.* 2014 Dec 19.
52. Vici P, Crispo A, Giordano A, Di Lauro L, Sperati F, Terrenato I, Pizzuti L, Sergi D, Mottolese M, Botti C, Grimaldi M, Capasso I, D'Aiuto G, Di Bonito M, Di Paola F, Maugeri-Saccà M, Montella M, **Barba M**. Anthropometric, metabolic and molecular determinants of human epidermal growth factor receptor 2 expression in luminal B breast cancer. *J Cell Physiol.* 2014 Dec 16.
53. Akl EA, Kahale LA, Ballout RA, **Barba M**, Yosucio VE, van Doormaal FF, Middeldorp S, Bryant A, Schünemann H. Parenteral anticoagulation in ambulatory patients with cancer.

54. Maugeri-Saccà M, Vici P, Di Lauro L, **Barba M**, Amoreo CA, Gallo E, Mottolese M, De Maria R. Cancer stem cells: are they responsible for treatment failure? *Future Oncol.* 2014 Oct;10(13):2033-44.
55. Akl EA, Ramly EP, Kahale LA, Yosuiico VE, **Barba M**, Sperati F, Cook D, Schünemann H. Anticoagulation for people with cancer and central venous catheters. *Cochrane Database Syst Rev.* 2014 Oct 15;10:CD006468. doi: 10.1002/14651858.CD006468.pub5.
56. Vici P, Mottolese M, Pizzuti L, **Barba M**, Sperati F, Terrenato I, Di Benedetto A, Natoli C, Gamucci T, Angelucci D, Ramieri MT, Di Lauro L, Sergi D, Bartucci M, Dattilo R, Pagliuca A, De Maria R, Maugeri-Saccà M. The Hippo transducer TAZ as a biomarker of pathological complete response in HER2-positive breast cancer patients treated with trastuzumab-based neoadjuvant therapy. *Oncotarget.* 2014 Oct 30;5(20):9619-25.
57. Di Lauro L, Vici P, **Barba M**, Pizzuti L, Sergi D, Rinaldi M, Di Benedetto A, Sperduti I, Shaaban AM, Speirs V, Mottolese M, De Maria R, Maugeri-Saccà M. Antiandrogen therapy in metastatic male breast cancer: results from an updated analysis in an expanded case series. *Breast Cancer Res Treat.* 2014 Nov;148(1):73-80. doi: 10.1007/s10549-014-3138-9.
58. Vici P, Pizzuti L, Natoli C, Moscetti L, Mentuccia L, Vaccaro A, Sergi D, Di Lauro L, Trenta P, Seminara P, Santini D, Iezzi L, Tinari N, Bertolini I, Sini V, Mottolese M, Giannarelli D, Giotta F, Maugeri-Saccà M, **Barba M**, Marchetti P, Michelotti A, Sperduti I, Gamucci T. Outcomes of HER2-positive early breast cancer patients in the pre-trastuzumab and trastuzumab eras: a real-world multicenter observational analysis. The RETROHER study. *Breast Cancer Res Treat.* 2014 Oct;147(3):599-607. doi: 10.1007/s10549-014-3133-1.
59. Maugeri-Saccà M, **Barba M**, Vici P, Pizzuti L, Sergi D, De Maria R, Di Lauro L. Aromatase inhibitors for metastatic male breast cancer: molecular, endocrine, and clinical considerations. *Breast Cancer Res Treat.* 2014 Sep;147(2):227-35. doi: 10.1007/s10549-014-3087-3. Epub 2014 Aug 13
60. Vici P, Sperati F, Maugeri-Saccà M, Melucci E, Di Benedetto A, Di Lauro L, Pizzuti L, Sergi D, Terrenato I, Esposito L, Iannuzzi CA, Pasquale R, Botti C, Fuhrman B, Giordano A, Mottolese M, **Barba M**. p53 status as effect modifier of the association between pre-treatment fasting glucose and breast cancer outcomes in non diabetic, HER2 positive patients treated with trastuzumab. *Oncotarget.* 2014 Jun 5.
61. Akl EA, Kahale L, **Barba M**, Neumann I, Labedi N, Terrenato I, Sperati F, Muti P, Schünemann H. Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer. *Cochrane Database Syst Rev.* 2014 Jul 8;7:CD006650. doi: 10.1002/14651858.CD006650.pub4.
62. Akl EA, Kahale L, Terrenato I, Neumann I, Yosuiico VE, **Barba M**, Sperati F, Schünemann H. Oral anticoagulation in patients with cancer who have no therapeutic or prophylactic indication for anticoagulation. *Cochrane Database Syst Rev.* 2014 Jul 1;7:CD006466. doi: 10.1002/14651858.CD006466.pub5.
63. Akl EA, Kahale L, Sperati F, Neumann I, Labedi N, Terrenato I, **Barba M**, Sempos EV, Muti P, Cook D, Schünemann H. Low molecular weight heparin versus unfractionated heparin for perioperative thromboprophylaxis in patients with cancer. *Cochrane Database Syst Rev.* 2014 Jun 26;6:CD009447. doi: 10.1002/14651858.CD009447.pub2.
64. Akl EA, Kahale L, Neumann I, **Barba M**, Sperati F, Terrenato I, Muti P, Schünemann H. Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer. *Cochrane Database Syst Rev.* 2014 Jun 19;6:CD006649. doi: 10.1002/14651858.CD006649.pub6.
65. Akl EA, Kahale L, Terrenato I, Neumann I, Yosuiico VE, **Barba M**, Sperati F, Schünemann H. Oral anticoagulation in patients with cancer who have no therapeutic or prophylactic indication for anticoagulation. *Cochrane Database Syst Rev.* 2014 Jun 4;6:CD006466. doi: 10.1002/14651858.CD006466.pub4.
66. Vici P, Mariani L, Pizzuti L, Sergi D, Di Lauro L, Vizza E, Tomao F, Tomao S, Mancini E, Vincenzoni C, **Barba M**, Maugeri-Saccà M, Giovinzano G, Venuti A. Emerging biological treatments for uterine cervical carcinoma. *J Cancer* 2014; 5(2): 86-97.
67. Crispo A, ***Barba M**, Malvezzi M, Arpino G, Grimaldi M, Rosso T, Sergi D, Giordano A, Montella M. Cancer mortality trends between 1988 and 2009 in the Metropolitan Area of Naples and Caserta, Southern Italy: results from a joint point regression analysis. *Cancer Biology and Therapy.* Accepted (September 2013). * equal contributors

68. Di Lauro L, Vici P, Del Medico P, Laudadio L, Tomao S, Giannarelli D, Pizzuti L, Sergi D, **Barba M**, Maugeri-Saccà M. Letrozole combined with gonadotropin-releasing hormone analog for metastatic male breast cancer. *Breast Cancer Res Treat*. 2013 Aug 28.
69. Vici P, Sergi D, Pizzuti L, Mariani L, Arena MG, **Barba M**, Maugeri-Saccà M, Vincenzoni C, Vizza E, Corrado G, Carpano S, Paoletti G, Tomao F, Tomao S, Giannarelli D, Di Lauro L. Gemcitabine-oxaliplatin (GEMOX) as salvage treatment in heavily pretreated platinum-resistant epithelial ovarian cancer patients. *J Exp Clin Cancer Res*. 2013 Aug 8;32(1):49. [Epub ahead of print].
70. Crispo A, **Barba M**, Grimaldi M, Malvezzi M, Ciliberto G and Montella M. Mortality trends for Liver Cancer in Southern Italy: a comparison with Italian data. *European Journal of Gastroenterology & Hepatology. Eur J Gastroenterol Hepatol*. 2014 Feb;26(2):245-6. In press.
71. *Crispo A, ***Barba M**, D'Aiuto G, De Laurentiis M, Grimaldi M, Rinaldo M, Caolo G, D'Aiuto M, Capasso I, Esposito E, Amore A, Di Bonito M, Botti G and Montella M. Molecular profiles of screen detected vs. symptomatic breast cancer and their impact on survival: results from a clinical series. *BMC Cancer*. In Press.
 - a. *These authors contributed equally to this work
72. Piscitelli P, **Barba M**, Crespi M, Di Maio M, Santoriello A, D'Aiuto M, Fucito A, Losco A, Pentimalli F, Maranta P, Chitano G, Argentiero A, Neglia C, Distanto A, Di Tanna G, Brandi ML, Mazza A, Marino IR, Giordano A. The burden of breast cancer in Italy: mastectomies and quadrantectomies performed between 2001 and 2008 based on the Nationwide Hospital Discharge Records. *Journal of Experimental Clinical Cancer Research*. In press.
73. Barbara J. Fuhrman, Louise A. Brinton, Ruth M. Pfeiffer, Barbara E. Teter, Celia Byrne, Cher Dallal, **Maddalena Barba**, Paola C. Muti, Gretchen L. Gierach. Estrogen metabolism and mammographic density in postmenopausal women: a cross-sectional study. *Cancer Epidemiology Biomarkers & Prevention. Cancer Epidemiol Biomarkers Prev*. 2012 Jun 26. [Epub ahead of print] PMID:22736791
74. **Maddalena Barba**, Francesca Sperati, Saverio Stranges, Chiara Carlomagno, Guglielmo Nasti, Vincenzo Iaffaioli, Marcella Mottolese, Irene Terrenato, Patrizia Vici, Giuseppina Caolo, Danila Serpico, Antonio Giordano, D'Aiuto Giuseppe, Anna Crispo, Maurizio Montella, Gabriele Capurso, Gianfranco delle Fave, Barbara Fuhrman and Sabino De Placido. Fasting Glucose and treatment outcome in breast and colorectal cancer patients treated with targeted agents: results from a historic cohort. *Annals of Oncology* 2011; doi: 10.1093/annonc/mdr540.
75. Akl EA, Labedi N, Terrenato I, **Barba M**, Sperati F, Sempos EV, Muti P, Cook D, Schünemann H. Low molecular weight heparin versus unfractionated heparin for perioperative thromboprophylaxis in patients with cancer. *Cochrane Database Syst Rev*. 2011 Nov 9;11:CD009447.
76. **Barba M**, Mazza A, Guerriero C, Di Maio M, Romeo F, Maranta P, Marino IR, Paggi MG, Giordano A. Wasting lives: the effects of toxic waste exposure on health. The case of Campania, Southern Italy. *Cancer Biology and Therapy*. In Press (date of acceptance: 22nd June 2011).
77. Akl EA, Gunukula S, **Barba M**, Yosucio VE, van Doormaal FF, Kuipers S, Middeldorp S, Dickinson HO, Bryant A, Schünemann H. Parenteral anticoagulation in patients with cancer who have no therapeutic or prophylactic indication for anticoagulation. *Cochrane Database Syst Rev*. 2011 Apr 13;4:CD006652. Review.
78. Akl EA, Vasireddi SR, Gunukula S, **Barba M**, Sperati F, Terrenato I, Muti P, Schünemann H. Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer. *Cochrane Database Syst Rev*. 2011 Apr 13;4:CD006649. Review.

79. Akl EA, Vasireddi SR, Gunukula S, Yosucio VE, **Barba M**, Sperati F, Cook D, Schünemann H. Anticoagulation for patients with cancer and central venous catheters. *Cochrane Database Syst Rev.* 2011 Apr 13;4:CD006468. Review.
80. Akl EA, Vasireddi SR, Gunukula S, **Barba M**, Sperati F, Terrenato I, Muti P, Schünemann H. Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer. *Cochrane Database Syst Rev.* 2011 Feb 16;2:CD006649. Review.
81. Akl EA, Vasireddi SR, Gunukula S, Yosucio VE, **Barba M**, Sperati F, Cook D, Schünemann H. Anticoagulation for patients with cancer and central venous catheters. *Cochrane Database Syst Rev.* 2011 Feb 16;2:CD006468. Review.
82. Akl EA, Gunukula S, **Barba M**, Yosucio VE, van Doormaal FF, Kuipers S, Middeldorp S, Dickinson HO, Bryant A, Schünemann H. Parenteral anticoagulation in patients with cancer who have no therapeutic or prophylactic indication for anticoagulation. *Cochrane Database Syst Rev.* 2011 Jan 19;1:CD006652.
83. Akl EA, Vasireddi SR, Gunukula S, Yosucio VE, **Barba M**, Terrenato I, Sperati F, Schünemann H. Oral anticoagulation in patients with cancer who have no therapeutic or prophylactic indication for anticoagulation. *Cochrane Database Syst Rev.* 2010 Dec 8;12:CD006466.
84. **Barba M**, Felsani A, Rinaldi M, Giunta S, Malorni W, Paggi MG. Reducing the risk of overdiagnosis in lung cancer: A support from molecular biology. *J Cell Physiol.* 2010 Dec 6.
85. Holger Schunemann, Francesca Sperati, **Maddalena Barba**, Nancy Santesso, Camilla Melegari, Elie Akl, Gordon Guyatt and Paola Muti. An instrument to assess quality of life in relation to nutrition: item generation, item reduction and initial validation. *Health Qual Life Outcomes* 2010 Mar 11;8(1):26.
86. Crispo A, Montella M, **Barba M**, Schittulli F, Grimaldi M, Serravezza G, Savastano C, Botti G, D'Aiuto G. Association Between Mode of Breast Cancer Detection and Diagnosis Delay. *The Breast* 2009 October 29.
87. **Maddalena Barba**, Li Yang, Holger J. Schünemann, Francesca Sperati, Sara Grioni, Saverio Stranges, Kim C. Westerlind, Giovanni Blandino, Michele Gallucci, Rossella Lauria, Luca Malorni and Paola Muti. Urinary estrogen metabolites and prostate cancer: a case-control study and meta-analysis. *Journal of Experimental & Clinical Cancer Research* 2009, **28**:135.
88. **Barba M**, Muti P. Is it time to test Metformin in breast cancer prevention trials? A reply to the authors. *Cancer Epidemiol Biomarkers Prev.* 2009 Sep;18(9):2565.
89. Muti P, Berrino F, Krough V, Villarini A, **Barba M**, Strano S, Blandino G. Metformin, diet and breast cancer. An avenue for chemoprevention. *Cell Cycle* 8:16, 1-1; 15 August 2009.
90. **Barba M**, Schünemann HJ, Sperati F, Akl EA, Musicco F, Guyatt G, Muti P. The effects of metformin on endogenous androgens and sex-hormone binding globulin in women: a systematic review and meta-analysis. *Clin Endocrinol (Oxf).* 2009 May;70(5):661-70. Epub 2008 Oct 21.
91. Frasci G, Crispo A, D'Aiuto G, **Barba M**, Rinaldo M, De Marco M, Grimaldi M, Papasso I, Botti G, Di Bonito M, Montella M. Outcome analysis of breast cancer patients receiving breast-conserving surgery in Southern Italy. *Journal of Chemotherapy. J Chemother.* 2008 Apr;20(2):269-77.
92. Akl EA, Terrenato I, **Barba M**, Sperati F, Muti P, Schünemann HJ. Extended perioperative thromboprophylaxis in patients with cancer. A systematic review. *Thromb Haemost.* 2008 Dec;100(6):1176-80.
93. Akl EA, Rohilla S, **Barba M**, Sperati F, Terrenato I, Muti P, Bdair F, Schünemann HJ. Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer: a systematic review. *Cancer.* 2008 Oct 1;113(7):1685-94. Review.
94. Akl EA, **Barba M**, Rohilla S, Terrenato I, Sperati F, Muti P, Schünemann HJ. Low-molecular-weight heparins are superior to vitamin K antagonists for the long term treatment of venous thromboembolism in patients with cancer: a cochrane systematic review. *J Exp Clin Cancer Res.* 2008 Jul 18;27:21. Review.

95. Akl EA, van Doormaal FF, **Barba M**, Kamath G, Kim SY, Kuipers S, Middeldorp S, Yosuico V, Dickinson HO, Schünemann HJ. Parenteral anticoagulation may prolong the survival of patients with limited small cell lung cancer: a Cochrane systematic review. *J Exp Clin Cancer Res*. 2008 May 15;27:4. Review.
96. Akl EA, Terrenato I, **Barba M**, Sperati F, Sempos EV, Muti P, Cook DJ, Schünemann HJ. Low-molecular-weight heparin vs unfractionated heparin for perioperative thromboprophylaxis in patients with cancer: a systematic review and meta-analysis. *Arch Intern Med*. 2008 Jun 23;168(12):1261-9. Review.
97. Akl E, **Barba M**, Rohilla S, Terrenato I, Sperati F, Muti P, Schünemann H. Anticoagulation for the long term treatment of venous thromboembolism in patients with cancer. *Cochrane Database Syst Rev*. 2008 Apr 16;(2):CD006650.
98. Akl EA, Kamath G, Yosuico V, Kim SY, **Barba M**, Sperati F, Cook DJ, Schünemann HJ. Thromboprophylaxis for patients with cancer and central venous catheters: a systematic review and a meta-analysis. *Cancer*. 2008 Jun;112(11):2483-92. Review.
99. **Maddalena Barba**, Irene Terrenato, Holger J. Schünemann, Barbara Fuhrman, Barbara Teter, Michele Gallucci , Alberto D'Amato, Paola Muti. Indicators of sexual and somatic development and adolescent body size in relation to prostate cancer risk: results from a case-control study. *Urology*. 2008 Jul;72(1):183-7. Epub 2008 Feb 15.
100. Akl E, Rohilla S, **Barba M**, Sperati F, Terrenato I, Muti P, Schünemann H. Anticoagulation for initial treatment of venous thromboembolism in patients with cancer. *Cochrane Database Syst Rev*. 2008 Jan 23;(1): CD006649
101. Fuhrman BJ, Teter BE, **Barba M**, Byrne C, Cavalleri A, Grant BJ, Horvath PJ, Morelli D, Venturelli E, Muti P. Equol status modifies the association of soy intake and mammographic density in a sample of postmenopausal women. *Cancer Epidemiol Biomarkers Prev*. 2008 Jan;17(1):33-42.
102. Akl E, Kamath G, Kim S, Yosuico V, **Barba M**, Terrenato I, Sperati F, Schünemann H. Oral anticoagulants may prolong the survival of a subgroup of patients with cancer: a Cochrane Systematic Review. *Journal of Experimental and Clinical Cancer Research*, 2007. 26 (2): p. 175-184.
103. Akl, E.A., van Doormaal FF, **Barba M**, Kamath G, Kim SY, Kuipers S, Middeldorp S, Yosuico V, Schünemann HJS. Parenteral anticoagulation for prolonging survival in patients with cancer who have no other indication for anticoagulation. *The Cochrane Database of Systematic Reviews* 2007(3).
104. Akl EA, Kamath G, Yosuico V, Kim SY, **Barba M**, Sperati F, Cook D, Schünemann HJ. Anticoagulation for thrombosis prophylaxis in cancer patients with central venous catheters. *Cochrane Database Syst Rev*. 2007 Jul 18;(3):CD006468. Review.
105. Akl EA, Kamath G, Kim SY, Yosuico V, **Barba M**, Terrenato I, Sperati F, Schünemann HJ. Oral anticoagulation for prolonging survival in patients with cancer. *Cochrane Database Syst Rev*. 2007 Apr 18;(2):CD006466. Review.
106. **Maddalena Barba**, Adalberto Cavalleri, Holger J. Schünemann, Vittorio Krogh, Alberto Evangelista, Giorgio Secreto, Andrea Micheli, Qi Zhou, Barbara Fuhrman, Barbara Teter, Franco Berrino, Paola Muti. Reliability of urinary 6-sulfatoxymelatonin as a biomarker in breast cancer. *Int J Biol Markers*. 2006 Oct-Dec;21(4):242-5.
107. **Maddalena Barba**, Susan E. McCann, Jing Nie, Domenica Vito, Saverio Stranges, Barbara Fuhrman, Maurizio Trevisan, Paola Muti, Jo L. Freudenheim. Perinatal Exposures and Breast Cancer Risk in the Western New York Exposures and Breast Cancer (WEB) Study. *Cancer Causes Control*. 2006 May;17(4):395-401.
108. Fuhrman B, **Barba M**, Schunemann HJ, Hurd T, Quattrin T, Cartagena R, Carruba G, Muti P. Basal growth hormone concentrations in blood and the risk for prostate cancer: A case-control study. *Prostate*. 2005 Jul 1;64(2):109-15.
109. Barbara J.Fuhrman, **Maddalena Barba**, Vittorio Krogh, Andrea Micheli,Valeria Pala, Rossella Lauria, Veronique Chajes, Elio Riboli, Sabina Sieri, Franco Berrino, Paola Muti. Erythrocyte membrane phospholipid composition as a biomarker of dietary fat. *Ann Nutr Metab*. 2005 Dec 21;50(2):95-102.
110. Platek M, Krogh V, Micheli A, Browne R, Meneghini E, Sieri S, Schunemann HJ, Pala V, **Barba M**, Wilding GE, Berrino F, Muti P. Serum fructosamine and subsequent breast cancer risk: a nested case-control study in the ORDET prospective cohort study. *Cancer Epidemiol Biomarkers Prev*. 2005 Jan;14(1):271-4.

111. **Barba M**, McCann SE, Schunemann HJ, Stranges S, Fuhrman B, De Placido S, Carruba G, Freudenheim JL, Trevisan M, Russell M, Nochajski T, Muti P. Lifetime total and beverage specific - alcohol intake and prostate cancer risk: a case-control study. *Nutr J.* 2004 Dec 9;3(1):23.

Capitoli in Libri

1. Sabrina Strano, **Maddalena Barba**, Paola Muti. Espressione Genica e Modulazione dei Determinati Ambientali nell'Eziopatogenesi delle Patologie Neoplastiche. In: Il manifesto della Lunga Vita. Edited by Marandola P, Marotta F. Sperling & Kupfer Publications, 2007.
2. **Maddalena Barba**, Barbara Fuhrman, Barbara Teter, Paola Muti. Epidemiology of breast, prostate and colon cancer in Western Societies. In: Nutrition and Cancer Prevention. Edited by Awad AB, Bradford PG. Texas: Culinary and Hospitality Industry Publications Services; 2005:3-25.
3. **Maddalena Barba**, Barbara Fuhrman, Paola Muti. Cancer Epidemiology. Fundamentals of Medical Oncology. Edited by Cavalli F, Cognetti F, Costa A, Orecchia R. Milan: Elsevier; 2006:3-13.

COMUNICAZIONI A CONGRESSI

Congressi Nazionali ed Internazionali

1. De Laurentiis M, Costanzo R, Di Lorenzo G, Lauria R, Caputo F, **Barba M**, Simeone E, Ferrara C, Petillo L, D'Agostino D, Bianco AR, De Placido S. "Studio MAM-1 GOCSI: uno studio randomizzato con disegno fattoriale di un trattamento adiuvante in pazienti con cancro precoce alla mammella (EBC) risultati linfonodo+ (N+)" Atti delle Giornate Scientifiche del Polo delle Scienze e delle Tecnologie per la Vita: Facoltà di Medicina e Chirurgia, Farmacia, Medicina Veterinaria ed Agraria, Università degli Studi di Napoli "Federico II". Abs pag. 400, Abstract book. Napoli, 6-7 giugno 2002.
2. Vernaglia A, Carlomagno C, De Laurentiis M, Milano L, Costanzo R, Di Lorenzo G, Lauria R, Caputo F, **Barba M**, Simeone E, Ferrara C, Silvestro L, Zingone L, Pennacchia R, Esposito A, Montagna E, Petillo L, D'Agostino D, Bianco AR, De Placido S. "Studio MAM-2 GOCSI: uno studio randomizzato multicentrico di fase III per verificare l'efficacia della terapia sequenziale con epirubicina e CMF nel tumore mammario" Atti delle Giornate Scientifiche del Polo delle Scienze e delle Tecnologie per la Vita: Facoltà di Medicina e Chirurgia, Farmacia, Medicina Veterinaria ed Agraria, Università degli Studi di Napoli "Federico II". Abs pag. 401, Abstract book. Napoli, 6-7 giugno 2002.
3. **Maddalena Barba**, Susan E McCann, Holger Schünemann, Saverio Stranges, Barbara Fuhrman, Sabino De Placido, Giuseppe Carruba, Jo L. Freudenheim, Maurizio Trevisan, Marcia Russell, Tom Nochajski, Paola Muti, "Total and beverage specific lifetime alcohol intake and risk of prostate cancer: a case-control study", Poster presentation at AACR Annual Meeting, March 29, 2004 in Orlando, FL.
4. **Maddalena Barba**, Adalberto Cavalleri, Holger J. Schünemann, Vittorio Krogh, Alberto Evangelista, Giorgio Secreto, Andrea Micheli, Qi Zhou, Barbara Fuhrman, Barbara Teter, Franco Berrino, Paola Muti. Effects of different storage temperatures on 6-Sulfatoxymelatonin concentration in urine. Poster presentation at the Fourth Annual AACR International Conference, October 31th, 2005, Baltimore, Maryland.
5. **Maddalena Barba**, MD, Susan E. Mac Cann, PhD, Jing Nie, PhD, Paola Muti, MD, MS, Saverio Stranges, MD, PhD, Barbara Fuhrman, MS, Maurizio Trevisan, MD, Jo L Freudenheim, PhD, "Perinatal exposures and breast cancer risk: a case-control study". Poster presentation at AACR Annual Meeting, April 2005, Anaheim, California.
6. **Maddalena Barba**, Irene Terrenato, Holger J. Schünemann, Barbara Fuhrman, Barbara Teter, Michele Gallucci, Paola Muti. Secondary sexual characteristics and adolescent body size in relation to risk of prostate cancer: results from a case-control study. Poster Presentation at the 2006 AACR Annual Meeting, April 3, 2006, Washington, DC.

7. Barbara Teter, Barbara Fuhrman, **Maddalena Barba** and Paola Muti. Aspirin Use and Mammographic Density as a marker of Breast Cancer Risk in Postmenopausal Women". Accepted for Poster Presentation at the 2007 AACR annual meeting.
8. Barbara Fuhrman, Barbara Teter, **Maddalena Barba**, Celia Byrne, Brydon Grant, Peter Horvath, and Paola Muti. Equal Status Modifies the Cross-sectional Association of Soy Intake with Mammographic Density in a Sample of Postmenopausal Women. Accepted for Poster Presentation at the 2007 AACR annual meeting.
9. **Maddalena Barba**, Li Yang, Holger J. Schünemann, Francesca Sperati, Sara Grioni, Saverio Stranges, Kim C. Westerlind, Giovanni Blandino, Michele Gallucci, Rossella Lauria, Luca Malorni and Paola Muti. Urinary estrogen metabolites and prostate cancer: a case-control study and meta-analysis. Accepted for Poster Presentation at the 2009 AACR annual meeting.
10. **Barba Maddalena**, Sperati Francesca, Carlomagno Chiara, De Placido Sabino, Nasti Guglielmo, Iaffaioli Vincenzo, Caolo Giuseppina, Serpico Danila, Crispo Anna, Capurso Gabriele, Delle Fave Gianfranco, Muti Paola. Fasting Glucose as a predictive Marker of Outcomes in Metastatic Colorectal Cancer Patients Treated with Avastin- and Erbitux-based Regimens: Null Results from the AVEC Study. 30 October 2010, Naples, Italy.

Presentazioni Orali:

1. *Invited speaker at the EPS Global International Cancer Symposium. "Urinary estrogen metabolites and prostate cancer: a case-control study and meta-analysis", July 10, 2010, Nanjing, China.
2. *Invited speaker at the Sciences' 3rd World Cancer Congress-Breast Cancer Conference. "Fighting Breast Cancer at Molecular Level", April 25, 2010, Shanghai, China.
3. ***Maddalena Barba**. Vegetarian vs. Meat-based dietary regimens in Cancer. October 8, 2009, Italian Association for Animal Support (AVA), Rome, Italy.
4. ***Maddalena Barba**, "Metabolic Syndrome and Cancer Risk: epidemiological aspects". Invited presentation. La Sapienza University, Latina, 23rd October 2009.
5. ***Maddalena Barba**, "Prevention in Breast Cancer". Invited presentation at the L.I.L.T. convention on Prevention. Rome, 26 November 2008.
6. ***Maddalena Barba**, "Epidemiologic Estimates and Risk Factors in Prostate Cancer: Overview". Invited presentation at the Satellite Workshop on Prostate Cancer within the 136th Advanced Course on Steroid Enzymes and Cancer. Ettore Majorana Foundation and Centre for Scientific Culture. Satellite, Erice, May the 8th, 2008.
7. ***Maddalena Barba** "La ricerca: conoscenze sull'alimentazione come causa dei tumori". Invited presentation for the National Association of Biodynamic Agriculture, Pavia, 20/04/2008.
8. ***Maddalena Barba**, "Campania: screening a che punto siamo?". Invited presentation for the European Woman (Europa Donna) Annual Forum; Naples, 11/16/2007.
9. ***Maddalena Barba**, "Foudamental tenents in the Prevention of Chronic Diseases". Invited presentation for the AIRC, Rome, 03/19/2007.
10. ***Maddalena Barba**, "Breast Cancer in Young Women". Invited presentation, Centro Alti Studi Difesa, Rome, 10/06/2006.
11. ***Maddalena Barba**, "Metabolic Syndrome and Colorectal Cancer". Invited presentation, III Convegno Internazionale di Chirurgia Digestiva, Asti, 09/23/2006.
12. ***Maddalena Barba**, "Metabolic Syndrome and Cancer". Invited presentation, Pisa, 07/08/2006.

13. ***Maddalena Barba**, "Dietary Supplements and Cancer Prevention: what's the evidence?" Invited presentation at La Sapienza University of Rome, May 6, 2006.
14. ***Maddalena Barba**, "Estrogens in pancreatic cancer: a theory to be reconsidered and revised", Regina Elena National Cancer Institute, Rome, Italy, September 23th, 2005.
15. ***Maddalena Barba**, Paola Muti, "Cosa e' cambiato nell'epidemiologia dei tumori della sfera ginecologica?", Innovazione e problemi aperti in oncologia ginecologica, V corso educazionale AIOM Lazio, November 29th, 2004, Rome, Italy.
16. ***Maddalena Barba**, Susan E McCann, Holger Schünemann, Saverio Stranges, Barbara Fuhrman, Sabino De Placido, Giuseppe Carruba, Jo L. Freudenheim, Maurizio Trevisan, Marcia Russell, Tom Nochajski, Paola Muti, "Total and beverage specific lifetime alcohol intake and risk of prostate cancer: a case-control study", Departmental Seminar, Department of Social and Preventive Medicine, SUNY at Buffalo, March 5th, 2003, in Buffalo, NY.

CAPACITÀ E COMPETENZE

PERSONALI

Acquisite nel corso della vita e della carriera ma non necessariamente riconosciute da certificati e diplomi ufficiali.

PRIMA LINGUA: ITALIANO

ALTRE LINGUE

- Capacità di lettura
- Capacità di scrittura
- Capacità di espressione orale

Inglese

Eccellente

Eccellente

Eccellente

CAPACITÀ E COMPETENZE RELAZIONALI

ECCELLENTI, ACQUISITE ED IMPLEMENTATE IN CORSO DI COLLABORAZIONI A CARATTERE SCIENTIFICO SVILUPPATE SIA A LIVELLO NAZIONALE CHE INTERNAZIONALE

CAPACITÀ E COMPETENZE ORGANIZZATIVE

ECCELLENTI, ACQUISITE ED IMPLEMENTATE IN CORSO DI COLLABORAZIONI A CARATTERE SCIENTIFICO SVILUPPATE SIA A LIVELLO NAZIONALE CHE INTERNAZIONALE

CAPACITÀ E COMPETENZE TECNICHE

RACCOLTA, ANALISI ED INTERPRETAZIONE DEI DATI PRODOTTI DA STUDI A CARATTERE SCIENTIFICO IN AMBITO ONCOLOGICO ED EPIDEMIOLOGICO. WRITING AI FINI DI PUBBLICAZIONE E GRANT APPLICATION .

PATENTE O PATENTI

B (auto)

ALLEGATI

[Se del caso, enumerare gli allegati al CV.]

Il sottoscritto è a conoscenza che, ai sensi dell'art. 26 della legge 15/68, le dichiarazioni mendaci, la falsità negli atti e l'uso di atti falsi sono puniti ai sensi del codice penale e delle leggi speciali. Inoltre, il sottoscritto autorizza al trattamento dei dati personali, ivi compresi quelli sensibili, ai sensi e per gli effetti del decreto legislativo 196/2003 per le finalità di cui al presente avviso di candidatura.

Data

Roma, 23 Giugno 2016

Firma Maddalena Barba